141 |
Contagion and inhabitation : the contemporary medical museum /Feng, Zhao Jin, January 1900 (has links)
Thesis (M. Arch.)--Carleton University, 2004. / Includes bibliographical references (p. 89-90). Also available in electronic format on the Internet.
|
142 |
Globalization and health knowledges in the Philippines tuberculosis and the infectious other /Ladia, Mary Ann J. January 2008 (has links)
Thesis (Ph.D.)--Michigan State University. Dept. of Anthropology, 2008. / Title from PDF t.p. (viewed on July 2, 2009) Includes bibliographical references (p. 145-166). Also issued in print.
|
143 |
Immunity and the carrier state a thesis submitted in partial fulfillment ... Master of Public Health ... /Johnson, Alfhild J. January 1946 (has links)
Thesis (M.P.H.)--University of Michigan, 1946.
|
144 |
Mathematical modeling of diseases to inform health policyFaissol, Daniel Mello January 2008 (has links)
Thesis (Ph.D.)--Industrial and Systems Engineering, Georgia Institute of Technology, 2008. / Committee Chair: Julie Swann; Committee Co-Chair: Paul Griffin; Committee Member: David Goldsman; Committee Member: Pinar Keskinocak; Committee Member: Thomas Gift
|
145 |
Integro-differential-equation models in ecology and epidemiology /Medlock, Jan P., January 2004 (has links)
Thesis (Ph. D.)--University of Washington, 2004. / Vita. Includes bibliographical references (p. 73-77).
|
146 |
Disease, development, and defining indigenous identity : the emergence of machupo virus in post-revolutionary Bolivia /Moore, Michelle Welty. January 2005 (has links)
Thesis (M.A.)--University of North Carolina at Wilmington, 2005. / Includes bibliographical references (leaves: 157-172)
|
147 |
Immunity and the carrier state a thesis submitted in partial fulfillment ... Master of Public Health ... /Johnson, Alfhild J. January 1946 (has links)
Thesis (M.P.H.)--University of Michigan, 1946.
|
148 |
A study of diseases in wildlife of South TexasCook, Robert S. January 1966 (has links)
Thesis (Ph. D.)--University of Wisconsin, 1966. / Typescript. Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.
|
149 |
The passage of water and dissolved material from the subarchnoid space through the orbitEyster, Alice Brownell. January 1943 (has links)
Thesis (Ph. D.)--University of Wisconsin, 1943. / Typescript (carbon copy). Some plates accompanied with leaf of explanatory text. Most ill. are laid in photographs. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaf [29]).
|
150 |
Estudos in vitro e in vivo de compostos furoxânicos, benzofuroxânicos e quinoxalinas com potencial aplicação para o tratamento da tuberculose /Souza, Paula Carolina de. January 2017 (has links)
Orientador: Fernando Rogério Pavan / Banca: Mario Hiroyuki Hirata / Banca:Rosilene Fressatti Cardoso / Banca: Jean Leandro dos Santos / Banca: Carla Raquel Fontana / Resumo: A busca por novos fármacos faz-se necessária sob dois principais pontos: a cura/tratamento do paciente pela melhora de qualidade de vida e a importância de tratalo a fim de eliminar focos de propagação das doenças infecto-contagiosas. A tuberculose (TB) se insere neste panorama, visto que é uma doença infecciosa que tem como principal patógeno o Mycobacterium tuberculosis (Mtb). A taxa de mortalidade da TB caiu 45% desde 1990 e o mundo estaria a caminho de atingir a meta global de redução de 50% até o ano de 2015. A última pesquisa conduzida no ano de 2015 mostrou 6,3 milhões de casos de TB notificados pelos programas nacionais da doença, dos quais 55% correspondem a casos de co-infecção TB-HIV. Uma recente problemática repercute: a resistência. Fato comprovado pela estimativa de 580.000 novos casos de TB-MDR no ano de 2015 comparados aos 480.000 casos registrados em 2014; e o relato de 9,7% desses casos serem na verdade TB-XDR. Baseado nesses dados epidemiológicos observamos a necessidade da busca de novos fármacos a fim de melhorar a terapia e consequentemente a qualidade de vida e cura dos pacientes. Nesse sentido, essa tese buscou investigar o potencial biológico de vinte e dois novos compostos n-óxidos: derivados furoxânicos, benzofuroxânicos e derivados quinoxalínicos; in vitro e in vivo. Investigamos também a segurança e dados preliminares ao mecanismo de ação. Os compostos demonstraram atividade (CIM90) entre 0,40 - 62 µM. Dentre todos os compostos n-óxidos estudados,... (Resumo completo, clicar acesso eletrônico abaixo) / Abtract: The search for new drugs is necessary under two main points: the cure / treatment of the patient for the improvement of quality of life and the importance of treating it in order to eliminate outbreaks of the spread of infecto-contagious diseases. Tuberculosis (TB) is part of this scenario, since TB is an infectious disease with Mycobacterium tuberculosis (Mtb) as its main pathogen. The TB mortality rate has dropped by 45% since 1990 and the world is on track to meet the global 50% reduction target by 2015. The latest survey conducted in 2015 showed 6.3 million TB cases notified by national disease programs, of which 55% correspond to cases of HIV-TB co-infection. A recent problem has repercussions: resistance. This is proven by the estimated 580,000 new cases of MDRTB in 2015 compared to 480,000 cases in 2014; actually 9.7% of these cases are TBXDR. Based on these epidemiological data, we observed the need to search for new drugs in order to improve therapy and consequently the quality of life and cure of patients. In this sense, this thesis sought to investigate the biological potential in vitro and in vivo of twenty-two new n-oxide compounds: furoxanic, benzofuroxanic and quinoxaline derivatives. We also investigated the safety and preliminary data on the mechanism of action of these compounds. The compounds showed activity (MIC90) in a ranging 0.40 to 62 µM. Among all the n-oxide studied, the benzofuroxan (8) was more promising (MIC90 values of 1.10 and 6.62 μM against the active and latent bacteria, respectively; and cytotoxicity against the MRC-5 cell line (IC50) was obtained at the concentration of 519.2 μM). This compound also showed activity against the monoresistant strains of important drugs of the therapy (isoniazid, rifampicin, moxifloxacin, bedaquiline, cycloserine and streptomycin) as well as... (Complete abstract click electronic access below) / Doutor
|
Page generated in 0.0674 seconds